Last reviewed · How we verify
DSXS
DSXS is a small molecule that targets the SGLT2 receptor.
DSXS is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | DSXS |
|---|---|
| Also known as | Active, DSXS 1535 |
| Sponsor | Sun Pharmaceutical Industries, Inc. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, DSXS reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis (PHASE3)
- Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product (PHASE2)
- Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis (PHASE3)
- An Open Label, Safety Study to Assess the Potential for Adrenal Suppression. (PHASE2)
- Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis (PHASE2)
- Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis (PHASE2)
- Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis (PHASE3)
- A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DSXS CI brief — competitive landscape report
- DSXS updates RSS · CI watch RSS
- Sun Pharmaceutical Industries, Inc. portfolio CI